

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:
022328Orig1s000

OTHER REVIEW(S)

505(b)(2) ASSESSMENT

Application Information		
NDA # 22328	NDA Supplement #:S-	Efficacy Supplement Type SE-
Proprietary Name: <u>Intermezzo</u> Established/Proper Name: <u>zolpidem tartrate SL</u> Dosage Form: <u>SL tablets</u> Strengths: <u>1.75 mg and 3.5 mg oral SL tablets</u>		
Applicant: <u>Transcept Pharma, Inc.</u>		
Date of Receipt: <u>original submission 9/30/08; re-sub 1/14/11; re-sub 9/27/11</u>		
PDUFA Goal Date: <u>11/27/11</u>	Action Goal Date (if different): <u>11/23/11</u>	
Proposed Indication(s): <u>as needed, middle-of-the- night (MOTN) insomnia</u>		

GENERAL INFORMATION

1. Is this application for a drug that is an “old” antibiotic as described in the Guidance to Industry, Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act? (Certain antibiotics are not entitled to Hatch-Waxman patent listing and exclusivity benefits.)

YES NO

If “YES,” proceed to question #3.

2. Is this application for a recombinant or biologically-derived product and/or protein or peptide product?

YES NO

If “YES “contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.



**INFORMATION PROVIDED VIA RELIANCE
(LISTED DRUG OR LITERATURE)**

3. List the information essential to the approval of the proposed drug that is provided by reliance on our previous finding of safety and efficacy for a listed drug or by reliance on published literature. *(If not clearly identified by the applicant, this information can usually be derived from annotated labeling.)*

Source of information (e.g., published literature, name of referenced product)	Information provided (e.g., pharmacokinetic data, or specific sections of labeling)
NDA 19908 Ambien (zolpidem tartrate)	Three Biopharm studies; specific sections PI changed
	Five clinical studies; specific sections PI changed

4. Reliance on information regarding another product (whether a previously approved product or from published literature) must be scientifically appropriate. An applicant needs to provide a scientific “bridge” to demonstrate the relationship of the referenced and proposed products. Describe how the applicant bridged the proposed product to the referenced product(s). (Example: BA/BE studies)

This NDA comprises of the following 3 single-dose pharmacokinetic (PK)/ bioequivalence (BE) bridging studies in healthy adult and elderly subjects. Study ZI-15, provides comparative bioavailability information relative to reference Ambien[®]. Study ZI-14 includes comparative bioavailability of Intermezzo[®] 1.75 mg and 3.5 mg in elderly and adult cohorts. Study ZI-13 provides a bridging link between IND formulation and final commercial formulation used in different studies. Final commercial formulation was used in most of the studies including pivotal BE, pharmacodynamic, and efficacy studies.

RELIANCE ON PUBLISHED LITERATURE

5. (a) Does the application rely on published literature to support the approval of the proposed drug product (i.e., the application *cannot* be approved without the published literature)?

YES NO

If “NO,” proceed to question #6.

- (b) Does any of the published literature necessary to support approval identify a specific (e.g., brand name) *listed* drug product?

YES Ambien (zolpidem tartrate) NO

If “NO”, proceed to question #6

If “YES”, list the listed drug(s) identified by name and answer question #5(c)

(c) Are the drug product(s) listed in (b) identified by the applicant as the listed drug(s)?

YES NO



RELIANCE ON LISTED DRUG(S)

Reliance on published literature which identifies a specific approved (listed) drug constitutes reliance on that listed drug. Please answer questions #6-10 accordingly.

6. Regardless of whether the applicant has explicitly referenced the listed drug(s), does the application **rely** on the finding of safety and effectiveness for one or more listed drugs (approved drugs) to support the approval of the proposed drug product (i.e., the application cannot be approved without this reliance)?

YES NO

If "NO," proceed to question #11.

7. Name of listed drug(s) relied upon, and the NDA/ANDA #(s). Please indicate if the applicant explicitly identified the product as being relied upon (see note below):

Name of Drug	NDA/ANDA #	Did applicant specify reliance on the product? (Y/N)
Ambien	19908	yes

Applicants should specify reliance on the 356h, in the cover letter, and/or with their patent certification/statement. If you believe there is reliance on a listed product that has not been explicitly identified as such by the applicant, please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

8. If this is a supplement, does the supplement rely upon the same listed drug(s) as the original (b)(2) application? N/A

YES NO

If "NO", please contact the (b)(2) review staff in the Immediate Office, Office of New Drugs.

9. Were any of the listed drug(s) relied upon for this application:

- a. Approved in a 505(b)(2) application?

YES NO

If "YES", please list which drug(s).

Name of drug(s) approved in a 505(b)(2) application: none

- b. Approved by the DESI process?

YES NO

If "YES", please list which drug(s).

Name of drug(s) approved via the DESI process:

- c. Described in a monograph?

YES NO

If "YES", please list which drug(s).

Name of drug(s) described in a monograph:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.